Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tego ScienceXKRX:191420 +7.37%60 Piotroski F-Score is 3 as of Aug. 11, 2026, which is 40% below its 10-year median of 5.00. GuruFocus rates XKRX:191420 with a GF Score™ of 60/100 and a GF Value™ of ₩13,240.01 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 977 Drug Manufacturers companies, Tego Science ranks worse than 77.79% on this metric.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Tego Science has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Tego Science's Piotroski F-Score or its related term are showing as below:
XKRX:191420'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 5 Max: 7
Current: 3
During the past 13 years, the highest Piotroski F-Score of Tego Science was 7. The lowest was 1. And the median was 5.
Tego Science (XKRX:191420) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Tego Science Piotroski F-Score Related Terms
Tego Science Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Tego Science's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tego Science's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tego Science Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tego Science's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Tego Science's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was -332.786 + -977.094 + -5044.701 + -2004.644 = ₩-8,359 Mil. Cash Flow from Operations was -464.742 + -824.406 + -1242.91 + -3178.551 = ₩-5,711 Mil. Revenue was 1616.134 + 1620.065 + 1392.415 + 1198.108 = ₩5,827 Mil. Gross Profit was 1093.108 + 1061.244 + 963.998 + 787.158 = ₩3,906 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(51840.433 + 82649.234 + 82179.18 + 78160.932 + 75051.724) / 5 = ₩73976.3006 Mil. Total Assets at the begining of this year (Mar25) was ₩51,840 Mil. Long-Term Debt & Capital Lease Obligation was ₩15,356 Mil. Total Current Assets was ₩55,067 Mil. Total Current Liabilities was ₩2,122 Mil.
Net Income was 4905.932 + 382.151 + -1280.833 + -657.845 = ₩3,349 Mil.
Revenue was 1897.38 + 1981.891 + 1606.156 + 1312.103 = ₩6,798 Mil. Gross Profit was 1349.889 + 1396.355 + 1183.82 + 917.369 = ₩4,847 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(48279.019 + 53180.786 + 53695.135 + 52515.371 + 51840.433) / 5 = ₩51902.1488 Mil. Total Assets at the begining of last year (Mar24) was ₩48,279 Mil. Long-Term Debt & Capital Lease Obligation was ₩286 Mil. Total Current Assets was ₩31,612 Mil. Total Current Liabilities was ₩2,304 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Tego Science's current Net Income (TTM) was -8,359.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Tego Science's return on assets of this year was -0.16124914. Tego Science's return on assets of last year was 0.069376.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Tego Science's gearing of this year was 0.20758126. Tego Science's gearing of last year was 0.00550181.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Tego Science's current ratio of this year was 25.94550079. Tego Science's current ratio of last year was 13.71962851.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Tego Science's number of shares in issue this year was 8.007. Tego Science's number of shares in issue last year was 8.022.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Tego Science's gross margin of this year was 0.67027533. Tego Science's gross margin of last year was 0.71311682.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Tego Science's asset turnover of this year was 0.11239725. Tego Science's asset turnover of last year was 0.14079677.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
0
+
1
+
1
+
0
+
0
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Tego Science has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Tego Science (XKRX:191420) has a Piotroski F-Score of 3 as of Aug. 11, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tego Science and its competitors. This is 40% below median its historical median of 5.00. Over the past decade, Tego Science's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Tego Science ranks #760 out of 977 companies in the Drug Manufacturers industry, placing it in the top 77.8%.
Is Tego Science's Piotroski F-Score too high?
Tego Science's current Piotroski F-Score of 3 is 40% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Tego Science's value of 3 is 40% below this industry median. Based on the distribution chart, Tego Science ranks #760 out of 977 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tego Science has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tego Science's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tego Science ranks #760 out of 977 companies for Piotroski F-Score. This places Tego Science in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Tego Science's value of 3 is 40% below this benchmark. Historically, Tego Science's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Tego Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tego Science's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tego Science and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tego Science's current Piotroski F-Score is 3, which is 40% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tego Science stock overvalued right now?
Based on GuruFocus' analysis, Tego Science (XKRX:191420) is currently considered Possible Value Trap. The stock's GF Value™ is ₩13,240.01, compared to a current price of ₩7,140.00 — trading 46.1% below its estimated fair value. The current Piotroski F-Score is 3, which is 40% below median its 10-year median of 5.00 and 40% below the Drug Manufacturers industry median of 5.00. Tego Science's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Tego Science (XKRX:191420), the current Piotroski F-Score is 3 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tego Science (XKRX:191420) Overvalued in 2026?
Based on GuruFocus' analysis, Tego Science stock appears to be undervalued.
The current stock price of ₩7,140.00 is trading 46.1% below its estimated GF Value™ of ₩13,240.01.
GuruFocus considers Tego Science to be Possible Value Trap.
Key valuation signals for XKRX:191420:
Piotroski F-Score: 3 (40% below median its 10-year median of 5.00)
GF Value™: ₩13,240.01 vs. price of ₩7,140.00 (46.1% below fair value)
Industry Position: 40% below the Drug Manufacturers median (#760 of 977)
No single metric tells the full story. See the XKRX:191420 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tego Science Inc is a biotech company that researches and develops regenerative medicine. It is engaged in the production of epidermis and cornea wound healing solution. Its products include Holoderm, SkinBank, Kaloderm, and Neoderm. It also provides testing services.
60GF Score
Get the complete analysis for XKRX:191420
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:191420 has been successfully added to your 
